European Post-Chicago Melanoma / Skin Cancer Meeting | Conference

Positive Results from First Randomized Study Assessing T-VEC/Ipilimumab Combo in Advanced Melanoma

July 7th 2017

The addition of T-VEC (T-VEC; Imlygic), a herpes simplex virus 1-based oncolytic virus, to CTLA-4 inhibitor ipilimumab (Yervoy) improves the objective response rate in patients with unresected stage IIIb to IV melanoma.

Dr. Schilling on the Importance of Distinguishing Ocular Melanoma

July 6th 2017

Bastian Schilling, MD, University of Wuerzburg, discusses different types of ocular melanoma and the importance of distinguishing this subtype.

Dr. Daud on the Combinations of Immunotherapy for Melanoma

July 6th 2017

Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma

July 6th 2017

Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.

PD-1/PD-L1 Inhibitors Arrive in Merkel Cell Carcinoma

July 1st 2017

Immune checkpoint inhibitors against PD-1 and PD-L1 are showing promise across clinical trials for patients with Merkel cell carcinoma.

Expert Discusses IDO/PD-1 and Other Emerging Combos in Melanoma

June 30th 2017

Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.

Dabrafenib Shows Remarkable Intracranial Activity in Patients With BRAF-Mutant Melanoma and Brain Metastases

June 30th 2017

Monotherapy with potent BRAF inhibitor dabrafenib (Tafinlar) resulted in a disease control rate of 83% in patients with BRAF-mutant melanoma and brain metastases.

Dr. Andtbacka on the OPTiM Results of T-VEC for Melanoma

June 30th 2017

Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.

Dr. Ross on the Treatment of Liver Metastasis in Melanoma

June 30th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.

Weighing Efficacy and Tolerability for Adjuvant Ipilimumab in Advanced Melanoma

June 30th 2017

Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.

Adjuvant PD-1 Inhibition on Horizon in Melanoma

June 30th 2017

Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.

Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma

June 29th 2017

Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.

Dr. Stratigos on the Prevention of Melanoma

June 29th 2017

Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.

Dr. Ascierto on Sequencing of Targeted Therapies for Melanoma

June 29th 2017

Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.